Answers are grounded in this paper and cite their sources.
Observational analysis shows elevated IL-6 and NF-κB activation in diabetic patients post-COVID, suggesting long-term inflammation risks.
IL-6 (interleukin 6), STAT3 (signal transducer and activator of transcription 3) and NF-κB (nuclear factor-κB) are the main factors causing cytokine storm in severe cases of COVID-19. The aim of the work was to establish the levels and activity of NF-κB, IL-6, and STAT3 in the post-COVID period (2024/2025) in diabetic patients who had COVID-19 in 2020–2022 compared to the pre-COVID (2018/2019) period. Plasma and blood mononuclear cells were used in the studies. The amount of IL-6 and STAT3 was determined by enzyme-linked immunosorbent assay and NF-κB activation by Western blotting. The amount of IL-6 in the blood plasma of diabetic patients who recovered from COVID-19 in 2020–2022 was higher than in healthy individuals and diabetic patients who did not have COVID-19. The highest level of STAT3 in the blood plasma is observed in diabetic patients who are guaranteed not to have COVID-19. In patients who have recovered from COVID-19, the amount of the factor is noticeably reduced. In the blood of diabetic and COVID-19 patients who took insulin, the amount of STAT3 increases. Determination of the expression of phospho-IKK and IκB in the blood mononuclear cells of patients showed an almost complete absence of phospho-IKK in patients who did not have COVID-19 and a high level of expression of this kinase in patients who recovered from COVID-19. The opposite pattern was observed for the NF-κB inhibitor, IκB. Thus, in patients who have recovered from COVID-19, activation of NF-κB is observed, which may be associated with inflammatory processes.
No takes yet. Share an insight, caveat, or question.
Pushkarev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: